Capricor Therapeutics Has a New Rating from Maxim Group

Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Capricor Therapeutics (NASDAQ: CAPR) today and set a price target of $7. The company’s shares closed yesterday at $1.30.

McCarthy noted:

“For Duchenne muscular dystrophy (DMD) there is one approved treatment, Exondys 51, but it is only indicated for 13% of the DMD population. Capricor’s CAP-1002 uses Cardiosphere-Derived Cells (CDCs) as a delivery system for exosomes to treat DMD and could reach the larger DMD population.”

According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 4.5% and a 43.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Currently, the analyst consensus on Capricor Therapeutics is Moderate Buy and the average price target is $8.60, representing a 561.5% upside.

In a report issued on May 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.60 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.25 and a one-year low of $0.63. Currently, Capricor Therapeutics has an average volume of 251.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.